Caroline Irene Piatek, MD
|
Title(s) | Clinical Associate Professor of Medicine (Clinician Educator) |
---|
School | Keck School of Medicine of Usc |
---|
Address | 1441 Eastlake Ave. Health Sciences Campus Los Angeles CA 90033
|
---|
vCard | Download vCard |
---|
|
|
Title(s) | Hematology/Oncology Fellowship Program Director |
---|
|
---|
Title(s) | Service Chief for Hematology at LAC+USC |
---|
|
---|
|
Biography
USC | 2012
-
| 2013 | Medical Oncology Fellow Research Award |
American Society of Clinical Oncology | 2014 | | Conquer Cancer Foundation Merit Award |
Keck School of Medicine of USC | 2014
-
| 2015 | Hematology Chief Fellow |
Overview
Dr. Carolne Piatek is an Associate Professor in the Jane Anne Nohl Division of Hematology at the Keck School of Medicine of USC. She is currently the fellowship director for the USC/LAC+USC Medical Hematology Fellowship Program. Dr. Piatek’s clinical focus is in non-malignant hematology. Her research interests include immune thrombocytopenia, warm autoimmune hemolytic anemia, cancer-associated thrombosis and paroxysmal nocturnal hemoglobinuria.
After earning her medical degree from Creighton University School of Medicine, Dr. Piatek completed internal medicine residency and hematology/medical oncology fellowship at the University of Southern California.
Bibliographic
Altmetrics Details
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media.
(Note that publications are often cited in additional ways that are not shown here.)
Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication.
Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.)
Click a Field or Translation tag to filter the publications.
-
Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2025 Jan 22.
Kulasekararaj A, Brodsky R, Schrezenmeier H, Griffin M, Röth A, Piatek C, Ogawa M, Yu J, Patel AS, Patel Y, Notaro R, Usuki K, Kulagin A, Gualandro S, Füreder W, Peffault de Latour R, Szer J, Lee JW. PMID: 39841198.
View in:
PubMed Mentions: Fields:
-
Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH. Blood. 2024 Dec 19.
Kulasekararaj AG, Griffin M, Piatek CI, Shammo J, Nishimura JI, Patriquin CJ, Schrezenmeier H, Barcellini W, Panse JP, Gaya A, Patel Y, Liu P, Filippov G, Sicre de Fontbrune F, Risitano AM, Lee JW. PMID: 39700502.
View in:
PubMed Mentions: Fields:
-
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. Lancet Haematol. 2023 Dec; 10(12):e955-e965.
Lee JW, Griffin M, Kim JS, Lee Lee LW, Piatek C, Nishimura JI, Carrillo Infante C, Jain D, Liu P, Filippov G, Sicre de Fontbrune F, Risitano A, Kulasekararaj AG, ALXN2040-PNH-301 Investigators. PMID: 38030318.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCTClinical Trials
-
Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD). Am J Hematol. 2024 01; 99(1):79-87.
Kuter DJ, Piatek C, Röth A, Siddiqui A, Numerof RP, Dummer W, FORWARD study group. PMID: 37929318.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up. Adv Ther. 2023 Jan; 40(1):211-232.
Yenerel MN, Sicre de Fontbrune F, Piatek C, Sahin F, Füreder W, Ortiz S, Ogawa M, Ozol-Godfrey A, Sierra JR, Szer J. PMID: 36272026; PMCID: PMC9589670.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab. Eur J Haematol. 2021 Mar; 106(3):389-397.
Kulasekararaj AG, Hill A, Langemeijer S, Wells R, González Fernández FA, Gaya A, Ojeda Gutierrez E, Piatek CI, Mitchell L, Usuki K, Bosi A, Brodsky RA, Ogawa M, Yu J, Ortiz S, Röth A, Lee JW, Peffault de Latour R. PMID: 33301613; PMCID: PMC8246907.
View in:
PubMed Mentions:
22 Fields:
Translation:
HumansCTClinical Trials
-
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS One. 2020; 15(9):e0237497.
Peipert JD, Kulasekararaj AG, Gaya A, Langemeijer SMC, Yount S, Gonzalez-Fernandez FA, Ojeda Gutierrez E, Martens C, Sparling A, Webster KA, Cella D, Tomazos I, Ogawa M, Piatek CI, Wells R, Sicre de Fontbrune F, Röth A, Mitchell L, Hill A, Kaiser K. PMID: 32886668; PMCID: PMC7473546.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCTClinical Trials
-
A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia. Acta Haematol. 2020; 143(3):244-249.
Piatek CI, Bocian H, Algaze S, Weitz IC, O'Connell C, Liebman HA. PMID: 31665725.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Case Report: Oxaliplatin-Induced Immune-Mediated Thrombocytopenia. Case Rep Oncol. 2018 Sep-Dec; 11(3):880-882.
Pan E, Hsieh E, Piatek C. PMID: 30687065; PMCID: PMC6341312.
View in:
PubMed Mentions:
4
-
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019 02 07; 133(6):540-549.
Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, Gaya A, Lee JW, Gutierrez EO, Piatek CI, Szer J, Risitano A, Nakao S, Bachman E, Shafner L, Damokosh AI, Ortiz S, Röth A, Peffault de Latour R. PMID: 30510079; PMCID: PMC6368201.
View in:
PubMed Mentions:
146 Fields:
Translation:
HumansCTClinical Trials
-
Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome. Acta Haematol. 2017; 138(3):129-137.
Piatek CI, Vergara-Lluri ME, Pullarkat V, Siddiqi IN, O'Connell C, Brynes RK, Feinstein DI. PMID: 28866671.
View in:
PubMed Mentions:
8 Fields:
Translation:
Humans
-
Value of routine staging imaging studies for patients with stage III breast cancer. J Surg Oncol. 2016 Dec; 114(8):917-921.
Piatek CI, Ji L, Kaur C, Russell CA, Tripathy D, Church T, Sposto R, Sener SF, Garcia AA. PMID: 27642105.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin. Thromb Res. 2016 Apr; 140 Suppl 1:S174.
Piatek CI, Tagawa ST, Wei-Tsai D, Hanna D, Weitz IC, O'Connell C, Rochanda L, Groshen S, Liebman HA. PMID: 27161687.
View in:
PubMed Mentions:
1 Fields:
-
An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians. Korean J Fam Med. 2015 Sep; 36(5):197-202.
Granatowicz A, Piatek CI, Moschiano E, El-Hemaidi I, Armitage JD, Akhtari M. PMID: 26435808; PMCID: PMC4591383.
View in:
PubMed Mentions:
25
-
Management of immune-mediated cytopenias in pregnancy. Autoimmun Rev. 2015 Sep; 14(9):806-11.
Piatek CI, El-Hemaidi I, Feinstein DI, Liebman HA, Akhtari M. PMID: 25981747.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Thrombocytopenia: optimizing approaches in cancer patients. Oncology (Williston Park). 2015 Apr; 29(4):297-8.
Piatek C, Akhtari M. PMID: 25952494.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34.
Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn DI, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA. PMID: 25374407.
View in:
PubMed Mentions:
4 Fields:
Translation:
HumansCTClinical Trials
-
Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature. Hum Pathol. 2014 Nov; 45(11):2183-91.
Vergara-Lluri ME, Piatek CI, Pullarkat V, Siddiqi IN, O'Connell C, Feinstein DI, Brynes RK. PMID: 25282037.
View in:
PubMed Mentions:
29 Fields:
Translation:
Humans
-
Unsuspected pulmonary embolism: impact on mortality among cancer patients. Curr Opin Pulm Med. 2012 Sep; 18(5):406-9.
Piatek C, O'Connell C. PMID: 22759768.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Treating venous thromboembolism in patients with cancer. Expert Rev Hematol. 2012 Apr; 5(2):201-9.
Piatek C, O'Connell CL, Liebman HA. PMID: 22475288; PMCID: PMC4435973.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans
-
Genetic screens for enhancers of brahma reveal functional interactions between the BRM chromatin-remodeling complex and the delta-notch signal transduction pathway in Drosophila. Genetics. 2005 Aug; 170(4):1761-74.
Armstrong JA, Sperling AS, Deuring R, Manning L, Moseley SL, Papoulas O, Piatek CI, Doe CQ, Tamkun JW. PMID: 15944353; PMCID: PMC1449748.
View in:
PubMed Mentions:
24 Fields:
Translation:
AnimalsCells
This graph shows the total number of publications by year. To see the data as text,
click here.
This graph shows the total number of publications by year. To return to the graph,
click here.
Year | Publications |
---|
2005 | 1 |
2012 | 2 |
2014 | 2 |
2015 | 3 |
2016 | 2 |
2017 | 1 |
2018 | 2 |
2019 | 1 |
2020 | 1 |
2021 | 1 |
2022 | 1 |
2023 | 2 |
2024 | 1 |
2025 | 1 |
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text,
click here.
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text,
click here.
newest
oldest
line numbers
double spacing
all authors
publication IDs